candidate

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease

November 20, 2024 07:00 ET | Source: Voyager Therapeutics, Inc. - Candidate VY1706 demonstrates significant reductions of tau at low…

1 day ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort…

2 weeks ago